Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;6(12):9657-68.
doi: 10.18632/oncotarget.3922.

Deubiquitinating enzymes as oncotargets

Urszula L McClurg  1 , Craig N Robson  1
Affiliations
Review

Deubiquitinating enzymes as oncotargets

Urszula L McClurg et al. Oncotarget. 2015.

Abstract

Carcinogenesis is a complex process tightly regulated at multiple levels by post-translational modifications. Epigenetics plays a major role in cancer development, all stable changes to the gene expression process that are not a result of a direct change in the DNA code are described as epigenetics. Epigenetic processes are regulated by post-translational modifications including ubiquitination which can directly affect either histones or transcription factors or may target their co-factors and interacting partners exerting an indirect effect. Deubiquitination of these target proteins is equally important and alterations in this pathway can also lead to cancer development, progression and metastasis. Only the correct, unaltered balance between ubiquitination and deubiquitination ensures healthy cellular homeostasis. In this review we focus on the role of deubiquitinating (DUB) enzymes in various aspects of epigenetics including the regulation of transcription factors, histone modifications, DNA damage repair pathways and cell cycle regulation. We discuss the impact of those processes on tumourigenesis and potential therapeutic applications of DUBs for cancer treatment.

Keywords: DUBs; androgen receptor; cancer; chromatin; deubiquitination; epigenetics; histones.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Authors have no conflict of interest.

Figures

Figure 1
Figure 1. Role of deubiquitinating enzymes in different aspects of cancer epigenetic regulation
See this image and copyright information in PMC

References

    1. Villamil MA, Liang Q, Zhuang Z. The WD40-repeat protein-containing deubiquitinase complex: catalysis, regulation, and potential for therapeutic intervention. Cell biochemistry and biophysics. 2013;67:111–126. - PMC - PubMed
    1. Blumenfeld N, Gonen H, Mayer A, Smith CE, Siegel NR, Schwartz AL, Ciechanover A. Purification and characterization of a novel species of ubiquitin-carrier protein, E2, that is involved in degradation of non-”N-end rule” protein substrates. The Journal of biological chemistry. 1994;269:9574–9581. - PubMed
    1. Ciechanover A, Heller H, Elias S, Haas AL, Hershko A. ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proceedings of the National Academy of Sciences of the United States of America. 1980;77:1365–1368. - PMC - PubMed
    1. Komander D. The emerging complexity of protein ubiquitination. Biochemical Society transactions. 2009;37:937–953. - PubMed
    1. Martinez-Forero I, Rouzaut A, Palazon A, Dubrot J, Melero I. Lysine 63 polyubiquitination in immunotherapy and in cancer-promoting inflammation. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009;15:6751–6757. - PubMed

Publication types

MeSH terms

LinkOut - more resources